It's official: The Pfizer-AstraZeneca deal talk can resume

Let the speculation continue: The window to another Pfizer-AstraZeneca bidding round is now open, per U.K. takeover rules. As of Tuesday, AstraZeneca ($AZN) can legally invite Pfizer ($PFE) to negotiate a deal. Pfizer could make its own one-time-only offer in private. But Pfizer can't take it upon itself to rebid in public until November. And what are the chances that the hard-to-get AstraZeneca will volunteer for another dance with its U.S.-based rival? Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.